tbuckley/cabot-search huggingface dataset:
Abstract 4228: Objective Judgment in Dobutamine Stress Echocardiography: Visualization of Post-Systolic Shortening by Tissue Doppler Imaging
Authors: Toshinari Onishi, Masaaki Uematsu, Nobuaki Tanaka, Shinsuke Nanto, Takakazu Morozumi, Tetsuya Watanabe, Masaki Awata, Osamu Iida, Kenji Kawamoto, Fusako Sera, Hitoshi Minamiguchi, Masamichi Yano, Kuniyasu Ikeoka, Shin Okamoto, Haruyo Yasui, Takayuki Ishihara, Tomoharu Dohi, Seiki Nagata
Journal: Circulation (2008)

Background: Although dobutamine stress echocardiography (DSE) is widely used for the detection of coronary artery disease (CAD), interpretation requires expertise. Post-systolic shortening (PSS) is a sensitive maker of myocardial ischemia. We have developed a novel tissue Doppler imaging (TDI) technique that readily visualizes the presence of PSS on 2-dimensional echocardiograms, and investigated whether CAD is objectively detectable by using this technique during DSE. Methods: Detection of diastolic abnormality by displacement Imaging (DADI): PSS was detected by using tissue Doppler displacement timing analysis. In this method, end-systole was automatically determined from tissue velocity, and delays of the displacement peaks from the end-systole were displayed from green to red on the left ventricular apical views, depending on the preset time window. DSE was performed in consecutive 51 patients prior to coronary angiography (CAG) who underwent diagnostic CAG for suspected CAD, and presented with normal LV wall motion at rest (male=31, age ranged 44 – 83 years). We measured the time from the end-systole to displacement peak (ΔT) at each segment in the apical, mid and basal segments by the standard apical plane (long axis, 4 chamber and 2 chamber views). The optimal cut-off value of ΔT for discriminating normal from CAD was determined by receiver operating characteristic analysis. Finally, DADI was performed using the optimal ΔT. CAD was confirmed by CAG as having &gt;75% diameter stenosis. Results: Angiographic CAD was present in 31 patients (61%). DADI predicted CAD with sensitivity of 87%, specificity of 75%, negative predictive value of 79%, and predictive accuracy of 82% at the cut-ff ΔT of 80 ms at peak DSE. Conclusion: DADI was useful in making objective judgment in DSE by readily portraying the presence of PSS, a marker of myocardial ischemia, on 2-dimensional echocardiograms in patients with inducible myocardial ischemia.
Principles of Clinical Practice: An Introductory Textbook
Authors: Mark B. Mengel
Journal: Annals of Internal Medicine (1992)

1: A Historical Overview of Patient Care.- 2: Philosophical and Ethical Foundations of the Physician-Patient Relationship.- 3: Interviewing and History Taking.- 4: The Physical Examination.- 5: Clinical Decision Making.- 6: Clinical Management.- 7: Health Maintenance.- 8: The Doctor-Patient Relationship.- 9: The Family System.- 10: The Cultural World of the Patient.- 11: The Health Care System.- 12: Medical Ethics.- 13: Medical Malpractice.- 14: Medical Economics.- 15: Patient-Centered Care.- References.- Author Index.
Book on the Physician Himself and Things that Concern His Reputation and Success,
Authors: D. W. Cathell
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Authors: Andrew P. Ambrosy, Gregg C. Fonarow, Javed Butler, Ovidiu Chioncel, Stephen J. Greene, Muthiah Vaduganathan, Savina Nodari, Carolyn S.P. Lam, Naoki Sato, Ami N. Shah, Mihai Gheorghiade
Journal: Journal of the American College of Cardiology (2014)
Bin1 expression is lost in breast cancer
Authors: A. Ghaneie, J. B. Duhadaway, V. Zemba-Palko, G. C. Prendergast
Journal: Journal of Clinical Oncology (2006)

10772 Background: Immune evasion is a major factor that limits the success of current treatment strategies with cytotoxic agents and immune therapy for breast cancer. Elevation of the immunomodulatory enzyme IDO in tumor cells was recognized as a mechanism of immune escape. Studies show that IDO is under genetic control of Bin1. Bin1 is a MYC-interacting adaptor protein which is attenuated in many malignancies and mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kB-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity. Mouse studies show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of therapy refractory tumors. These findings suggest that Bin1 loss promotes immune escape by deregulating IDO and that IDO inhibitors may improve response to cancer chemotherapy. Methods: A cohort of breast cancer specimens collected at our institution over a five-year period was used for this retrospective study. The cohort consists of 56 specimens of early stage and 37 specimens of advanced stage ductal adenocarcinomas of the breast. Using immunohistochemistry, specimens were examined for the loss of BIN1 expression. Results: Bin 1 was lost in a significant fraction of breast cancer specimens. In the early stage group 76% had loss of nuclear expression and 23% loss of cytoplasmic expression. In the advanced stage group 84% had loss of nuclear staining and 38% had loss of cytoplasmic staining. Conclusions: Bin1 was lost in a significant fraction of breast cancer specimens. This finding indicates that loss of Bin 1 may play a significant role in immune evasion in human breast cancer. Animal studies have shown that loss of Bin1 can be antagonized by IDO inhibitors. This could have a significant implication for the treatment of human breast cancer. Immune escape induced by Bin1 loss could be restored through the administration of immunomodulators such as 1MT (1-methyltryptophan) in combination with chemotherapy. This could lead to a novel approach in the treatment of breast cancer. No significant financial relationships to disclose.
A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity
Authors: M E Fabry, A Sengupta, S M Suzuka, F Costantini, E M Rubin, J Hofrichter, G Christoph, E Manci, D Culberson, S M Factor, R L Nagel
Journal: Blood (1995)
Abstract 12202: Sirt7 Deficiency Impaires Angiogenic Responses in a Mouse Model of Vascular Insufficiency
Authors: Yasuhiro Izumiya, Taku Rokutanda, Satoshi Araki, Shinsuke Hanatani, Takafumi Senokuchi, Eva Bober, Thomas Braun, Kazuya Yamagata, Hisao Ogawa
Journal: Circulation (2011)

Introduction: Sirt7, one of the seven members of the mammalian sirtuin family, is involved in the regulation of ribosomal gene transcription. To date, little information is available on the role of...
Assessing Clinical Competence.
Authors: Vic Neufeld, Geoffrey R. Norman
Journal: Annals of Internal Medicine (1985)

Rubella antibody screeningSir, Redhead and colleagues adopted the prag- matic approach suggested by the Immunization Practices Advisory Committee in the United States of America with respect to screening for rubella immunity.'The committee endors- es the view that a documented history of rubella vaccination can be considered presumptive evidence of immunity.2A retrospective survey of women aged between 16 and 39 years found to be rubella susceptible (that is, not immune) on opportunistic screening was carried out.The setting was a rural practice with a list size of 4600 patients.A list of women who were found to be susceptible to rubel- la was generated using a search of com- puterized patient records.The results of the computer search were checked against the written notes.Data were available from April 1988 until April 1994.During this period 559 women had been screened and 12 had been found to be susceptible to rubella.The notes of these 12 women were then reviewed and it was found that eight of them had a record in their notes of previous rubella vaccination.It would therefore appear unwise to assume that a documented history of vac- cination against rubella implies immunity in all women; repeated screening of rubel- la status is still required.
Early Cancer: Prevention, Detection, Course, Treatment.
Authors: Leonard B. Goldman
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cerebral Palsies of Children.
Authors: William Osler
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Final results of a phase I study of adjuvant chemoradiation for gastric adenocarcinoma with infusional 5-fluorouracil and bi-weekly cisplatin
Authors: Z. Kassam, H. MacKay, C. Buckley, J. Brierley, J. Kim, L. L. Siu, C. Swallow, S. Fung, A. M. Oza, J. Ringash
Journal: Journal of Clinical Oncology (2008)

15671 Background: This phase I study assessed the maximum tolerated dose (MTD) of 2-weekly cisplatin, infusional 5-FU and concurrent conformal radiotherapy (RT) for resected gastric cancer. Methods: Thirty four patients with resected stage IB to IV(M0) gastric adenocarcinoma were prescribed 12 weeks of infusional 5FU 200 mg/m2/day with RT 45Gy in 25 fractions starting at day 16. Cisplatin dose escalation occurred after a minimum of 3 patients without dose limiting toxicity (DLT) per cohort. DLT was defined as ≥ grade 3 toxicity requiring treatment or hospitalization; hematologic or biochemical changes not requiring treatment were not considered DLT. MTD was the highest dose level where no more than 1 of 6 patients had DLT. If 1 patient had DLT another 3 were treated at the same dose level. If ≥2 had DLT in any cohort that level exceeded MTD and the previous dose level was expanded to 6 patients. Results: Median age was 56 years (range 31–77); M:F 53:47%. Median follow up was 2.5 years (0.3–5). There were no grade 5 events. Five patients experienced DLT (see table). Cohort 5 had 2 patients with DLT exceeding MTD; cohort 4 was defined as the MTD. Acute toxicity included skin, weight loss, fatigue, anorexia, nausea, dehydration, hand-foot syndrome, sepsis, hyponatremia and hematological events. Eleven patients did not complete prescribed 5FU (cohort 1[1], 2[3], 3[3], 4[1], 5[3]) among whom the mean duration of 5FU received was 7 weeks (0.5–11). Of these 11 patients, 4 did not complete cisplatin (cohort 2[1], 5[3]); 3 did not complete RT on study receiving 0, 0 and 36Gy. One patient had late grade 3 toxicity: weight-loss and G-tube dependence. Nine patients relapsed of whom 6 died; 3-year overall and relapse free survival were 86% and 71% with median survival not reached. Conclusion: MTD occurred in cohort 4 with no DLT in this cohort. A phase II study is accruing patients using 12 weeks of infusional 5FU 200 mg/m2/day and 4 cycles cisplatin 40 mg/m2 2-weekly with RT 45Gy in 25 fractions starting at day 16. Acute and dose limiting toxicity in each cohort Cohort Cisplatin mg/m2 Cycles of cisplatin N Number of patients with toxicity Type of non hematological grade 3 toxicity+ All grade 1/2 Non-hematological grade 3 Hematological grade 3/4 1 0 0 6 6 1* 1 Sepsis* Hyponatremia 2 20 4 10 9 1* 0 Fatigue* 3 30 4 7 7 1* 4 Vomiting with dehyration* Stomatitis 4 40 4 6 6 2 0 Hyponatraemia not requiring treatment 5 40 5 5 5 2* 3 Anorexia* Dehyradtion* + Note that several patients experienced multiple non-hematologic and/or dose limiting toxicities; * Dose limiting toxicity No significant financial relationships to disclose.
Abstract 3801: Readmission for Heart Failure: 15 vs 30 Days
Authors: Hammam D Zmily, Suleiman Daifallah, Jareer O Farah, Ramanjit Kaur, Ibrahim Shaik, Azzat Ali, Husam Al Samarah, S. W Tam, Phillip Levy, Jalal K Ghali
Journal: Circulation (2009)

Background: Readmission within 30 days of discharge following hospitalization for heart failure (HF) is a target for a major imitative to reduce healthcare cost targeting primarily acute care hospi...
A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC).
Authors: R. K. Kelley, H. S. Nimeiri, M. T. Vergo, E. K. Bergsland, A. H. Ko, P. N. Munster, A. Reinert, M. F. Mulcahy, A. B. Benson, A. P. Venook
Journal: Journal of Clinical Oncology (2010)

TPS213 Background: The multikinase inhibitor SOR prolongs survival in patients with advanced HCC. Another pathway often active in HCC is mammalian target of rapamycin (mTOR). Preclinical studies suggest that mTOR inhibition impairs HCC tumor growth and angiogenesis. In HCC xenografts, the addition of an mTOR inhibitor to SOR enhances antitumor effect. Phase I studies of an mTOR inhibitor combined with SOR show acceptable toxicity but do not include HCC patients with liver disease. We have developed a 2-site phase I dose escalation trial of the mTOR inhibitor TEM plus SOR in patients with advanced HCC to determine safety and the maximum tolerated dose (MTD) which will be the recommended phase II dose of the combination. Pharmacokinetics (PK) of TEM and its primary metabolite will be performed in 6 patients (pts) at MTD. A future single arm, 2-stage phase II study with exploratory endpoints is planned to measure efficacy. The study was approved and funded by the National Comprehensive Cancer Network (NCCN) from general research support. Methods: Main eligibility criteria: Unresectable HCC diagnosed histologically or clinically. No prior systemic therapy (Tx). Prior resection and local Tx permitted if ≥1 untreated radiographically measurable site of disease. ECOG performance status ≤2. Child-Pugh score ≤7 points and bilirubin ≤2 mg/dL. Adequate organ and marrow function. Treatment: Starting dose level (DL 1) is TEM 15 mg IVweekly plus SOR 200 mg PO BID in 28-day cycles. Design: 3+3 dose escalation until MTD with dose-limiting toxicity (DLT) window of 28 days. 6 additional pts will be enrolled at MTD as PK cohort. Sample size for phase I: 9-30 pts. Primary endpoints: Safety and MTD. Other endpoints: PK for TEM in 6 pts at MTD. Viral load measurement in pts with viral hepatitis. Exploratory dynamic-contrast enhanced CT imaging, Choi response criteria, biomarkers (AFP, AFP-L3, and DCP), and circulating tumor cell measurements will be performed in PK cohort pts and all pts in ensuing phase II trial. Accrual information: 3 pts have enrolled to DL 1. Updated enrollment information will be provided. Dose level TEM (mg IV weekly) SOR (mg PO) −2 10 200 QD −1 15 200 QD 1 (starting dose) 15 200 BID 2 15 400 BID 3 25 400 BID 4 25 200 BID Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer-Onyx National Comprehensive Cancer Network
Abstract 1715: Necrotic Core and its Ratio to Dense Calcium are Predictors of High-risk Non-ST-Elevation Acute Coronary Syndromes: Results from the Prospective, Multi-center, Global VH-IVUS Registry
Authors: Eduardo Missel, Gary S Mintz, Stephane G Carlier, Jie Qian, Shoujie Shan, Celia Castellanos, Ryan K Kaple, George Dangas, Roxana Mehran, Jeffrey W Moses, Gregg W Stone, Martin B Leon
Journal: Circulation (2007)

Background: Increased CK-MB levels and ST-segment depression are predictors of a worse prognosis in the setting of acute coronary syndromes (ACS). We hypothesized a relationship between virtual histology intravascular ultrasound (VH-IVUS) findings and these prognostic factors. Methods and Results: We performed whole vessel VH-IVUS measurements in a consecutive series of 225 pts presenting with non ST-elevation (NSTE) ACS on admission; the four basic VH-IVUS coronary plaque components - fibrous (FI), fibro-fatty (FF), dense calcium (DC) and necrotic core (NC) - were measured and the NC/DC ratio calculated. Pts age was 62 ± 11 years with 72% males and 23% diabetics. Among VH-IVUS parameters, only the NC/DC ratio had a positive association to CK-MB levels (r=0.21, p=0.03); it was also significantly higher for ST-depression vs. non-ST-depression ACS (1.97±0.37 vs. 1.58±0.31, p=0.02). A NC/DC value ≥2 was the threshold that best separated high-risk NSTE ACS pts from those with neither abnormal CK-MB nor abnormal ECG findings (odds ratio 3.8, p=0.01), and a %NC ≥6 best enhanced the predictive value of the NC/DC ratio (odds ratio 3.1, p=0.04). Pts with both NC/DC value ≥2 and %NC ≥6 had significantly higher LDL-C (132.46±49.80 vs. 100.28±36.46, p=0.001) and more myocardial injury when compared to pts with no predictors (p=0.002, Figure ). Conclusions: Using VH-IVUS analysis, we identified parameters that were positively associated to a high-risk ACS presentation. Our results in-vivo reinforce previous histopathological findings that both a larger necrotic core content and less quantitative calcium are substrates for plaque vulnerability.
Biomedical applications of polymers derived by reversible addition – fragmentation chain-transfer (RAFT)
Authors: Benjamin D. Fairbanks, Pathiraja A. Gunatillake, Laurence Meagher
Journal: Advanced Drug Delivery Reviews (2015)

RAFT- mediated polymerization, providing control over polymer length and architecture as well as facilitating post polymerization modification of end groups, has been applied to virtually every facet of biomedical materials research. RAFT polymers have seen particularly extensive use in drug delivery research. Facile generation of functional and telechelic polymers permits straightforward conjugation to many therapeutic compounds while synthesis of amphiphilic block copolymers via RAFT allows for the generation of self-assembled structures capable of carrying therapeutic payloads. With the large and growing body of literature employing RAFT polymers as drug delivery aids and vehicles, concern over the potential toxicity of RAFT derived polymers has been raised. While literature exploring this complication is relatively limited, the emerging consensus may be summed up in three parts: toxicity of polymers generated with dithiobenzoate RAFT agents is observed at high concentrations but not with polymers generated with trithiocarbonate RAFT agents; even for polymers generated with dithiobenzoate RAFT agents, most reported applications call for concentrations well below the toxicity threshold; and RAFT end-groups may be easily removed via any of a variety of techniques that leave the polymer with no intrinsic toxicity attributable to the mechanism of polymerization. The low toxicity of RAFT-derived polymers and the ability to remove end groups via straightforward and scalable processes make RAFT technology a valuable tool for practically any application in which a polymer of defined molecular weight and architecture is desired.
Complementary Medicine: An Integrated Approach
Authors: G. T. Lewith, J. N. Kenyon, Peter J. Lewis
Journal: Annals of Internal Medicine (1997)

This guide to the common complementary therapies is written for primary care physicians, whose patients are increasingly consulting alternative therapies. The authors describe each of the major complementary techniques - their application, the expertise of the therapists and the training they undergo, and the evidence for their effectiveness - as they interact with conventional medicine in the management of 20 common disorders.
The Esophagus: Medical and Surgical Management
Authors: Edward Benson Benedict, George Lionel Nardi
Journal: Annals of Internal Medicine (1988)

This is indeed a Harvard Book, right out of the Medical School and the Massachusetts General Hospital. The authors are both M.D., F.A.C.S. In his Foreword, Dr. Churchill declares the authors to be "experts" who are here trying to unify under one cover all that has been written about the esophagus in so many different articles, essays, and books on general medicine. He thinks they have succeeded admirably; so do we. They are a bit annoyed at the complacency of the general practitioner who fails to be alerted by the patient's difficulty in swallowing. This may, of course, be the first sign of serious trouble, but not always. In cancer, for instance, there may be no striking symptom until the condition is inoperable. In spite of all the "helps" at hand, early diagnosis of cancer is seldom possible, that is to say, diagnosis which permits early surgery. It is rather